VA
PLRX icon

Verdad Advisers’s Pliant Therapeutics PLRX Stock Holding History

Verdad Advisers’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Buy
+98,320
New +$124K 0.14% 149

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Verdad Advisers's PLRX Position: Q1 2026 in Review

Verdad Advisers opened a new position in Pliant Therapeutics (PLRX) in Q1 2026: 98,320 shares worth $124K. The stake represents 0.14% of the portfolio and ranks #149 among its holdings.

91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Verdad Advisers held 98,320 shares of Pliant Therapeutics worth $124K as of Q1 2026.
  • Pliant Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Pliant Therapeutics made up 0.14% of Verdad Advisers's portfolio in Q1 2026, its #149 holding.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.